NASDAQ:MDWD

MediWound Competitors

$5.04
-0.10 (-1.95 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.91
Now: $5.04
$5.15
50-Day Range
$4.87
MA: $5.29
$5.77
52-Week Range
$1.73
Now: $5.04
$6.07
Volume55,375 shs
Average Volume154,058 shs
Market Capitalization$137.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

MediWound (NASDAQ:MDWD) Vs. CGC, APHA, CRON, TLRY, USNA, and ACB

Should you be buying MDWD stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to MediWound, including Canopy Growth (CGC), Aphria (APHA), Cronos Group (CRON), Tilray (TLRY), USANA Health Sciences (USNA), and Aurora Cannabis (ACB).

Canopy Growth (NASDAQ:CGC) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Canopy Growth and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Canopy Growth-312.84%-13.11%-9.66%
MediWound-53.12%-94.63%-29.86%

Risk and Volatility

Canopy Growth has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Canopy Growth and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Canopy Growth$297.34 million35.73$-993,370,000.00$1.3221.06
MediWound$31.79 million4.32$4.95 million$0.0863.00

MediWound has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.2% of Canopy Growth shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 0.3% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Canopy Growth and MediWound, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Canopy Growth510211.94
MediWound00403.00

Canopy Growth presently has a consensus price target of $35.6778, indicating a potential upside of 28.34%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Canopy Growth.

Summary

Canopy Growth beats MediWound on 9 of the 15 factors compared between the two stocks.

Aphria (NASDAQ:APHA) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Aphria and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
MediWound-53.12%-94.63%-29.86%

Risk and Volatility

Aphria has a beta of 2.67, indicating that its stock price is 167% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Aphria and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million11.03$-63,210,000.00($0.06)-235.67
MediWound$31.79 million4.32$4.95 million$0.0863.00

MediWound has lower revenue, but higher earnings than Aphria. Aphria is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.3% of Aphria shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Aphria and MediWound, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria05302.38
MediWound00403.00

Aphria presently has a consensus price target of $22.00, indicating a potential upside of 55.59%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given Aphria's higher possible upside, analysts clearly believe Aphria is more favorable than MediWound.

Summary

Aphria beats MediWound on 7 of the 13 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Cronos Group and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
MediWound-53.12%-94.63%-29.86%

Risk and Volatility

Cronos Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Valuation and Earnings

This table compares Cronos Group and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million117.46$1.17 billion$0.6712.48
MediWound$31.79 million4.32$4.95 million$0.0863.00

Cronos Group has higher earnings, but lower revenue than MediWound. Cronos Group is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

11.8% of Cronos Group shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 7.9% of Cronos Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for Cronos Group and MediWound, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24101.86
MediWound00403.00

Cronos Group presently has a consensus price target of $8.75, indicating a potential upside of 4.67%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Cronos Group.

Summary

Cronos Group beats MediWound on 9 of the 14 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Tilray and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
MediWound-53.12%-94.63%-29.86%

Insider & Institutional Ownership

12.6% of Tilray shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 16.8% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Tilray has a beta of 3.12, indicating that its stock price is 212% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Tilray and MediWound, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray19001.90
MediWound00403.00

Tilray presently has a consensus price target of $18.3078, indicating a potential upside of 6.44%. MediWound has a consensus price target of $7.50, indicating a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts clearly believe MediWound is more favorable than Tilray.

Valuation and Earnings

This table compares Tilray and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million17.69$-321,170,000.00($1.69)-10.18
MediWound$31.79 million4.32$4.95 million$0.0863.00

MediWound has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

USANA Health Sciences (NYSE:USNA) and MediWound (NASDAQ:MDWD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares USANA Health Sciences and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
MediWound-53.12%-94.63%-29.86%

Insider and Institutional Ownership

54.1% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. 45.4% of USANA Health Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

USANA Health Sciences has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for USANA Health Sciences and MediWound, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
MediWound00403.00

USANA Health Sciences currently has a consensus target price of $126.00, suggesting a potential upside of 27.41%. MediWound has a consensus target price of $7.50, suggesting a potential upside of 48.81%. Given MediWound's higher possible upside, analysts plainly believe MediWound is more favorable than USANA Health Sciences.

Earnings and Valuation

This table compares USANA Health Sciences and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.92$100.53 million$4.4122.42
MediWound$31.79 million4.32$4.95 million$0.0863.00

USANA Health Sciences has higher revenue and earnings than MediWound. USANA Health Sciences is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Summary

USANA Health Sciences beats MediWound on 9 of the 13 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Aurora Cannabis and MediWound's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
MediWound-53.12%-94.63%-29.86%

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 16.0% of MediWound shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Aurora Cannabis has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500. Comparatively, MediWound has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Aurora Cannabis and MediWound, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis69001.60
MediWound00403.00

Aurora Cannabis currently has a consensus target price of $10.9264, suggesting a potential upside of 38.66%. MediWound has a consensus target price of $7.50, suggesting a potential upside of 48.81%. Given MediWound's stronger consensus rating and higher possible upside, analysts plainly believe MediWound is more favorable than Aurora Cannabis.

Earnings and Valuation

This table compares Aurora Cannabis and MediWound's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million7.50$-2,468,190,000.00($2.86)-2.76
MediWound$31.79 million4.32$4.95 million$0.0863.00

MediWound has lower revenue, but higher earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Summary

MediWound beats Aurora Cannabis on 7 of the 13 factors compared between the two stocks.


MediWound Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Canopy Growth logo
CGC
Canopy Growth
1.0$27.80-1.4%$10.62 billion$297.34 million-8.32News Coverage
Aphria logo
APHA
Aphria
1.6$14.14-3.9%$4.48 billion$405.96 million-23.97Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
Cronos Group logo
CRON
Cronos Group
0.8$8.36-2.6%$3.01 billion$25.64 million34.83Analyst Downgrade
Tilray logo
TLRY
Tilray
1.0$17.20-1.5%$2.95 billion$166.98 million-3.79News Coverage
USANA Health Sciences logo
USNA
USANA Health Sciences
2.0$98.89-2.6%$2.04 billion$1.06 billion18.31Analyst Downgrade
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$7.88-1.1%$1.56 billion$207.89 million-0.32Analyst Downgrade
Sundial Growers logo
SNDL
Sundial Growers
1.0$0.85-1.2%$1.41 billion$75.86 million-0.33Analyst Upgrade
Gap Up
HEXO logo
HEXO
HEXO
1.1$5.52-3.3%$676.12 million$60.46 million-1.13Gap Up
ChromaDex logo
CDXC
ChromaDex
1.3$8.20-4.0%$547.41 million$46.29 million-21.58
Natural Alternatives International logo
NAII
Natural Alternatives International
0.4$18.20-6.3%$115.72 million$118.88 million227.53High Trading Volume
Increase in Short Interest
Gap Up
HAPP
Happiness Biotech Group
0.6$1.84-0.5%$47.53 million$65.06 million0.00Increase in Short Interest
News Coverage
Mannatech logo
MTEX
Mannatech
1.3$19.13-2.4%$39.58 million$157.73 million5.89Gap Down
FSD Pharma logo
HUGE
FSD Pharma
0.3$1.56-1.9%$29.89 million$190,000.00-0.35Increase in Short Interest
News Coverage
CYAN
Cyanotech
0.6$3.14-1.6%$19.15 million$31.90 million31.40
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.